{"id":4435,"date":"2026-11-18T09:00:00","date_gmt":"2026-11-18T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=4435"},"modified":"2026-11-19T20:46:09","modified_gmt":"2026-11-20T00:46:09","slug":"fda-approves-brain-penetrant-therapy-for-gaucher-type-3","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=4435","title":{"rendered":"FDA Approves Brain Penetrant Therapy for Gaucher Type 3"},"content":{"rendered":"<p><img fetchpriority=\"high\" decoding=\"async\" width=\"768\" height=\"432\" src=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261119_Sanofi_Infilbray_Therapeutic_Indications-768x432.png\" alt=\"\" class=\"attachment-medium_large size-medium_large wp-image-4438\" srcset=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261119_Sanofi_Infilbray_Therapeutic_Indications-768x432.png 768w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261119_Sanofi_Infilbray_Therapeutic_Indications-300x169.png 300w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261119_Sanofi_Infilbray_Therapeutic_Indications-1024x576.png 1024w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261119_Sanofi_Infilbray_Therapeutic_Indications-1536x864.png 1536w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261119_Sanofi_Infilbray_Therapeutic_Indications.png 1672w\" sizes=\"(max-width: 768px) 100vw, 768px\" \/><\/p>\n<p><strong>Company<\/strong><\/p>\n<p>Sanofi (Genzyme)<\/p>\n<p><strong>Event Type<\/strong><\/p>\n<p>FDA approval (previously missed 18 Nov action)<\/p>\n<p><strong>Modality<\/strong><\/p>\n<p>Oral glucosylceramide synthase inhibitor<\/p>\n<p><strong>Asset<\/strong><\/p>\n<p>Venglustat (Infilbray)<\/p>\n<p><strong>Target<\/strong><\/p>\n<p>Glucosylceramide synthase<\/p>\n<p><strong>Disease Area<\/strong><\/p>\n<p>Neurological symptoms of Gaucher disease type 3<\/p>\n<h4>Summary<\/h4>\n<p>FDA approved venglustat, Infilbray, on November 18 for neurological symptoms of Gaucher type 3 in adults and children weighing at least 15 kg. This is the first FDA-approved therapy for that neurological manifestation, with material psychiatric and reproductive safety cautions.<\/p>\n<p>FDA describes a randomized double-blind study of 43 enzyme-replacement-stabilized patients aged at least 12, comparing daily oral venglustat with continued intravenous enzyme replacement over 52 weeks. FDA reports improvement on a combined neurological measure. The approval belongs to Genzyme, a Sanofi company. This is a new regulatory action, not a new November 19 readout.<\/p>\n<h4>Deep Analysis<\/h4>\n<p><strong>Interpretation A:<\/strong> blood-brain-barrier penetration and glucosylceramide-synthase inhibition address substrate accumulation that enzyme replacement poorly reaches in the central nervous system.<\/p>\n<p><strong>Interpretation B:<\/strong> the small trial and composite endpoint limit precision about individual clinical functions, while mood and suicidal-ideation risks may constrain use. The 15 kg label threshold does not imply that every younger child was represented in the pivotal trial. Long-term neurodevelopment, durability and interaction with systemic disease care need follow-up.<\/p>\n<h4>Company and Product Background<\/h4>\n<p>Gaucher type 3 results from deficient glucocerebrosidase activity and glucosphingolipid accumulation, including in the brain. Venglustat inhibits glucosylceramide synthase to reduce substrate formation and crosses the blood-brain barrier.<\/p>\n<h4>Signal Extraction<\/h4>\n<ul>\n<li>FDA primary notice verifies approval, population, study design and risks.<\/li>\n<li>Missing: full label review, long-term comparative neurologic trajectories and access.<\/li>\n<li>Upgrade: durable improvement across functional domains.<\/li>\n<li>Downgrade: psychiatric safety burden or limited real-world benefit.<\/li>\n<li>Falsifier for CNS differentiation: no sustained neurologic advantage under controlled follow-up.<\/li>\n<\/ul>\n<h4>InSilens Take<\/h4>\n<p>This is a meaningful rare-disease regulatory advance with unresolved breadth and durability of benefit.<\/p>\n<h4>Signal Assessment<\/h4>\n<p>Signal Importance: 4 of 5. Signal Direction: positive. Confidence in Facts: High. Confidence in Interpretation: Moderate.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>FDA approved venglustat, Infilbray, on November 18 for neurological symptoms of Gaucher type 3 in adults and children weighing at least 15 kg. This is the first FDA-approved therapy for that neurological manifestation, with&#8230;<\/p>\n","protected":false},"author":1,"featured_media":4438,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[913,29,1555],"class_list":["post-4435","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-therapeutic-indication","tag-gaucher-disease","tag-sanofi","tag-venglustat"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4435","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4435"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4435\/revisions"}],"predecessor-version":[{"id":4451,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4435\/revisions\/4451"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/4438"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4435"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4435"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4435"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}